Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
The acquisition of Enci Therapeutics will advance Innova Therapeutics' lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is expressed in most solid and hematological cancers. IVT-8086 is the only cancer therapeutic that...
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).
CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an...